Mantle cell lymphoma (MCL) is a rare type of B-cell non-Hodgkin lymphoma (NHL).

It can occur in men and women of any age, but it most commonly affects men over 60 years old. The disease is called “mantle cell lymphoma” because the tumor cells come from white blood cells (B lymphocytes) that are found in the “mantle zone” of the lymph node. By the time a person is diagnosed, it is very common to have various regions of the body involved with MCL such as the lymph nodes, spleen, bone marrow, and gastrointestinal tract.

Although some patients may not need treatment at the time of diagnosis, MCL usually responds well to the first treatment. The amount and period of time of remission (disappearance of signs and symptoms) may be different depending on lymphoma biology and the kind of treatment given. Most patients will need treatment more than one time.

TREATMENT OPTIONS

There are a number of treatment options for the management of relapsed/refractory (returns after or no longer responds to treatment) MCL, and the number of treatment choices continues to increase. The type of treatment recommended depends on what treatments were already given, when the relapse took place, and the patient’s age and overall health.

The following agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory MCL:

- Acalabrutinib (Calquence)
- Bortezomib (Velcade)
- Ibrutinib (Imbruvica)
- Lenalidomide (Revlimid)
- Zanubrutinib (Brukinsa)
- Bexucabtagene autoleucel (Tecartus) (CAR-T cell therapy)

Although they are not approved to be given together, most of the drugs mentioned above may be used with rituximab (Rituxan) or rituximab biosimilars. Biosimilars are drugs that are modeled after a biologic therapy that already exists. Biosimilars include rituximab-abbs and rituximab-pvvr. Additional drugs and combinations of drugs that are commonly used for the treatment of relapsed/refractory MCL include:

- Bendamustine (Treanda) with or without rituximab (Rituxan)
- Combination chemotherapy with or without rituximab [Rituxan]

Stem cell transplant (SCT) can work well in patients with relapsed or refractory MCL. There are two types of SCTs: autologous (a patient’s own cells are put back into the patient after high-dose chemotherapy) and allogeneic (patients receive stem cells from another donor). Autologous SCT is generally given after a patient’s first therapy, but it may also work well for medically fit patients who have a good response to later therapies. Younger medically fit patients may consider allogeneic SCT as a possible cure, but SCT may have more risks.
There are several clinical trials investigating how safe and effective these new drugs are, either used alone or together with current or new therapies, for MCL that has already been treated. These include:

- Abexinostat
- ARQ 531
- Camidanlumab tesirine
- Carfilzomib (Kyprolis)
- Cirtmuzumab and VLS-101
- Copanlisib (Aliqopa)
- Enzalutamide (Xtandi)
- Everolimus (Afinitor)
- DTRM-555
- Parsaclisib
- Ixazomib (Ninlaro)
- Loncastuximab tesirine
- LOXO-305
- Mosunetuzumab
- Nivolumab (Opdivo)
- Obinutuzumab (Gazyva)
- Palbociclib (Ibrance)
- Pembrolizumab (Keytruda)
- REGN1979
- Temsirolimus (Torisel)
- Umbralisib
- Venetoclax (Venclexta)

Genetically engineered T cells, which are designed to recognize and kill MCL cells, are also being studied to treat MCL. This type of treatment is known as chimeric antigen receptor (CAR) T-cell therapy, and it includes drugs such as axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel, and tisagenlecleucel (Kymriah), and others. To learn more, please refer to the CAR T-Cell Therapy factsheet (click here).

Treatment choices are increasing as new drugs are developed and current treatments are improved. Because the science is always changing, it is important for patients to check in with their doctor or with LRF to find out about any new treatments that become available.

Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients with lymphoma. Because the optimal initial treatment of MCL is not clear and it is such a rare disease, clinical trials enrollment is critical for establishing more effective, less toxic treatments. The rarity of the disease also means that the latest treatments are often available only through clinical trials. Patients interested in participating in a clinical trial should view the Understanding Clinical Trials factsheet on LRF’s website (click here), talk to their physician, or contact the LRF’s website [click here], talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling (800) 500-9976 or emailing helpline@lymphoma.org.

Patients with lymphoma should have regular visits with a physician who is familiar with their medical history and the treatments they have received. Medical tests (such as blood tests, computed tomography [CT] scans, and positron emission tomography [PET] scans) may be required at various times during remission to evaluate the need for additional treatment. Periodically, it may be necessary to repeat a tumor biopsy to better understand the biology of the lymphoma.

Some treatments can cause long-term side effects or late side effects, which can vary based on duration and frequency of treatments, age, gender, and the overall health of each patient at the time of treatment. A physician will check for these side effects during follow-up care. Visits may become less frequent the longer the disease remains in remission.

Patients and their caregivers are encouraged to keep copies of all medical records and test results as well as information on the types, amounts, and duration of all treatments received. This documentation will be important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF’s award-winning Focus On Lymphoma mobile app (lymphoma.org/mobileapp) and the Lymphoma Care Plan (lymphoma.org/publications) can help patients manage this documentation.
**LRF’S HELPLINE AND LYMPHOMA SUPPORT NETWORK**

A lymphoma diagnosis often triggers a range of feelings and concerns. In addition, cancer treatment can cause physical discomfort. The LRF Helpline staff members are available to answer your general questions about a lymphoma diagnosis and treatment information, as well as provide individual support and referrals to you and your loved ones. Callers may request the services of a language interpreter. A part of the Helpline is LRF’s one-to-one peer support programs, Lymphoma Support Network. This program connects patients and caregivers with volunteers who have experience with MCL, similar treatments, or challenges, for mutual emotional support and encouragement. Patients and loved ones may find this useful whether the patient is newly diagnosed, in treatment, or in remission.

**MOBILE APP**

*Focus On Lymphoma* is the first mobile application (app) that provides patients and caregivers comprehensive content based on their lymphoma subtype, including MCL, and tools to help manage their lymphoma such as, keep track of medications and blood work, track symptoms, and document treatment side effects. The *Focus On Lymphoma* mobile app is available for download for iOS and Android devices in the Apple App Store and Google Play. For additional information on the mobile app, visit FocusOnLymphoma.org. To learn more about any of these resources, visit our website at lymphoma.org, or contact the LRF Helpline at 800-500-9976 or helpline@lymphoma.org.

**Resources**

LRF offers a wide range of free resources that address treatment options, the latest research advances, and ways to cope with all aspects of lymphoma and MCL. LRF also provides many educational activities, including our in-person meetings, podcasts, and webinars for people with lymphoma. For more information about any of these resources, visit our websites at lymphoma.org/MCL or lymphoma.org, or contact the LRF Helpline at [800] 500-9976 or helpline@lymphoma.org.

---

**LRF appreciates the expertise and review of our Editorial Committee:**

Leo I. Gordon, MD, FACP  
Co-Chair  
Robert H. Lurie Comprehensive Cancer Center of Northwestern University  
Kristie A. Blum, MD  
Co-Chair  
Emory University School of Medicine

John Allan  
Weill Cornell Medicine

Jennifer E. Amengual, MD  
Columbia University

Jonathon Cohen  
Emory University School of Medicine

Alex Herrera, MD  
City of Hope

Shana Jacobs, MD  
Children’s National Hospital

Manali Kamdar, MD  
University of Colorado

Peter Martin, MD, Weill Cornell Medicine

Anthony Mato, MD  
Memorial Sloan Kettering Cancer Center

Neha Mehta-Shah, MD, MSCI  
Washington University School of Medicine in St. Louis

Pierluigi Porcu, MD  
Thomas Jefferson University

**Contact LRF:**  
Helpline: [800] 500-9976  
Email: helpline@lymphoma.org  
www.lymphoma.org

---

Supported through grants from:  
Genentech  
Biomers  
PharmacyC’s  
Astellas  
Kite  
Beigene

The *Understanding Lymphoma* series is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person’s body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer’s institution, and LRF are not responsible for the medical care or treatment of any individual.

© 2021 Lymphoma Research Foundation

---

Last updated 2021